Global Pharma Quality summit focuses on vaccines

Hyderabad: The two-day Global Pharmaceutical Quality Summit-2022 organised by the Indian Pharmaceutical Alliance (IPA) successfully concluded. The event saw industry captains and regulators in the ecosystem deliberate on achieving excellence and quality in operations, vaccine development and sustainability. It also witnessed leaders across industries sharing their views on innovation, technology and the potential learnings for the pharmaceutical industry.

The highlight of the summit was the discussion on the 'Sustainable end-to-end Operations and Quality Excellence – Path Forward' that brought together the CEOs of leading Indian Pharmaceutical companies such as Cipla, Dr Reddy's, Lupin, Sun Pharma, Torrent and Zydus.

GV Prasad, co-chairman, Dr Reddy's, said: "While digitalisation is inevitable, there is still a challenge to digitise since underlying processes need to be mastered and understood to enhance efficacy of the digitisation process. Industry leaders will have to be more agile, make data-driven leadership decisions with science and common sense coming together."

"We have developed our technologies internally for generics and now we have to collaborate with the ones who have already done it and then leverage those. The talent required for some technologies is not present in India so collaboration with global partners will help address this issue," said Umang Vohra, CEO, Cipla.

IPA represents 24 research-based national pharmaceutical companies. Collectively, IPA companies account for over 85 per cent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country's exports of drugs and pharmaceuticals and service over 57 per cent of the domestic market.